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Geoffrey Krampitz, MD, PhD is a hepatopancreaticobiliary surgeon with an extensive background in surgical oncology,
stem cell science, and cancer immunotherapy research who recently joined the faculty here at Thomas Jefferson
University as an Assistant Professor of Surgery. After earning his BSE in biomedical engineering at Johns Hopkins
University and before starting medical training, Dr. Krampitz worked in consulting in the San Francisco Bay Area and
eventually helped launch two internet startup companies in Silicon Valley. He then went to UC San Francisco for his
Master’s degree, where he investigated the role of HIF1-alpha in stem cell differentiation. Dr. Krampitz received his
medical degree from and completed his surgical residency at Stanford University, where he also received a PhD in
Stem Cell Biology and Regenerative Medicine. He later completed a complex general surgical oncology fellowship at
MD Anderson Cancer Center. During medical school at Stanford, he studied VEGF signaling in adventitial stem cells
after vessel injury and its contribution to neo-intimal hyperplasia. During his general surgery residency at Stanford,
he completed his PhD thesis investigating pancreatic cancer stem cells and developing novel immunotherapies. His
current research focuses on identifying the key elements of programmed cell removal and “don’t-eat-me” signals that
can be targeted for clinical applications.
What made you interested in pursuing surgery?
My interest in medicine and surgery, in particular, started
when I was very young. I am originally from Costa Rica.
I actually lived on a coffee plantation in Guanacaste,
Costa Rica, where I had a picturesque life living in the
jungles and rainforest. My dad was an American who
moved to Costa Rica, and he was interested in oil
exploration and mineral exploration. He had businesses
all throughout South America, Latin America, and the
world. He had gold mines around the world, and one of
them was in Costa Rica. He had sold [this] gold mine to
another person, who was also an explant to Costa Rica,
and that person defaulted on the payments. My dad was
in the process of reclaiming the gold mine equipment,
and part of that involved an inspection. My mom went
down [to the mine] as did my dad, and when they arrived,
they were confronted by the person [he sold it to] and
his girlfriend, who then murdered my mother and father.
Their death provided a huge impetus for me to evaluate
medicine, surgery, and, initially, trauma surgery, as a
calling of mine.
In many ways I wanted to prevent others from enduring
the same loss and hardships that resulted from [my]
loss. I initially wanted to do trauma surgery because it
had that direct connection to what had happened to me,
my siblings, and my family. Also, growing up I didn’t have
family members in medicine or in surgery, so the closest
contact I had through college and then as a pre-medical
student applying to medical school were the shadowing
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opportunities that I had in the emergency room, which
led to shadowing opportunities in the operating room
with the trauma surgeons. So, to me it felt very natural,
not only from an inspirational perspective, but also from
an accessibility perspective, too.
During medical school at Stanford you founded the
Medical Mentorship Program and worked with the
Latino Medical Students Association. Could you speak
more on those experiences?
I mentioned earlier that I didn’t have any direct family ties
to medicine. Coming initially from a very disadvantaged
background, I think mentorship was hugely important. At
Johns Hopkins, making it into and throughout graduate
school, and getting into medical school and during
medical school, mentors played a huge role [for me]. At
every point along the way, I think mentorship has been the
foundation of my success. So, I certainly recognize that,
and realize that there are a lot of really disadvantaged
folks going through similar struggles to those that I went
through. I just wanted to help in some way to alleviate
that. At least, provide a path. I think when you’re climbing
up the ladder you really want to be able to reach down
and help the next person up the rung. So, that’s what I
wanted to do, and that was the inspiration for founding
[the Medical Mentorship Program].
When I got to Stanford, there were a lot of individual
mentoring programs, but nothing really cohesive with a
unifying message. What I did was try and organize some

of those already existing programs and also expand
that to help a lot of people, [which] was certainly a huge
team effort. [The program] was able to reach a lot of
the community colleges and other colleges in the Bay
Area to provide one-on-one mentorship with Stanford
medical students, develop workshops for improving
applications, facilitate bridging that gap, and try to get
more disadvantaged students to apply to and get into
medical school.
Are you still connected with the Medical Mentorship
Program? Have you been able to find ways to
incorporate advocacy as you’ve progressed through
your medical career?
Yeah! I still have ties to that program, which is still going
on at Stanford. It’s essentially part of a larger organization
within Stanford. I think one of the things that I wanted to
do was not build something that was a one-off that was
going to die as soon as I left. Part of what I wanted to
do was to build a lasting legacy, so to speak, where that
could continue on. I still go back; a couple of years ago I
went back and gave a talk to the new crop of mentees,
and I think that certainly recharged my batteries, so to
speak, [getting] to reconnect with the real people that I
wanted to help along the way.
You worked in Silicon Valley before starting medical
school. What did you do there, and what did you learn
there that informs your medical practice today?
I went to Johns Hopkins for college, and I majored in
biomedical engineering, so I had a lot of computational
background. When I finished college, I wanted to take a
year off between college and medical school. At this point,
it was the late nineties, and it was the height of the dotcom boom, and I really wanted to go out to San Francisco
and see what the excitement was about. I moved out
there and initially worked for a consulting company.
Then, as a result of that opportunity, I got involved in a
couple of internet startup companies in Silicon Valley.
What was intended to be a one-year break while I applied
to medical school turned into a six-year hiatus where I
became immersed in startup culture and what it takes
to build a startup company and wearing many hats.
You train as an engineer, but you’re also in many ways
a businessperson as well, and you learn a lot of those
skills. While working with clients - you’re representing the
company. You’re not only doing the technical aspects, but
also a lot of the other soft skills that come with building a
start-up company. Those were extremely helpful skills to
have regardless of what you go into.
After working in Silicon Valley, you pursued a MSE in

biomedical science focusing on stem cell research.
How did you decide to pursue that degree, and how did
it influence your decision to go into cancer research?
At the end of six years, the companies were doing very
well, and they were sold to larger entities. At the end
of that, I decided that six years was long enough to put
my real calling on hold. So, I went back and worked in a
lab at UCSF, where I did my Master’s thesis, and really
got back into the research world, specifically in stem
cells. That’s really what started my interest in stem cells
- working in Dr. Susan Fischer’s stem cell lab at UCSF.
After that point, I went to medical school at Stanford and
continued my real love for research while I was there. I
did a Howard Hughes fellowship year during medical
school there and worked on VEGF signaling in heart valve
development, and that led to looking at VEGF signaling in
adventitial stem cells. [I looked at] tissue-specific stem
cells in the vasculature and how they respond to vessel
injury and contribute to neo-intimal hyperplasia - which
is a big problem with cardiac stents and vascular stents
in general - and tried to figure out ways to mitigate that.
That led to a couple of other research fellowships and
foundational fellowships that really helped propel my
research work.
What made you interested specifically in surgical
oncology and hepatopancreaticobiliary cancer?
When I was in medical school, I developed another
mentor-mentee relationship with a surgical oncologist,
Dr. Jeff Norton, who is a legend in his own right. He has
one of those larger-than-life personalities, and it’s very
difficult not to become engrossed by his personality and
his energy, drive, and commitment to patients. So, while I
was rotating on his service, I really started to evaluate what
I wanted to do and what aligned with my own research
interests that I had developed over time, and I felt that
surgical oncology really fit the bill. It aligned my interests
in stem cells, cancer stem cells, and immunotherapies
with my love for doing complex operations and helping
people. Additionally, being inspired by someone of
that caliber drove me to do surgical oncology, and in
particular, pancreas and pancreaticobiliary surgery.
Your current research interest is in programmed cell
removal and immune-mediated signaling. What got
you interested in this specific area of oncology?
I stayed on at Stanford for my residency, and during
residency I worked with Dr. Jeff Norton and Dr. Irv
Weissman. I took some time off during my research
years in residency to get a PhD in stem cell biology
and regenerative medicine in Dr. Weissman’s lab. One
of the projects I did was looking at cancer stem cells
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within pancreatic neuroendocrine tumors, which hadn’t
been discovered yet. Part of that was driven by my own
interests in pancreatic neuroendocrine tumors and Dr.
Norton’s expertise in that area as well, but we also had
a very prominent member of the community that was
afflicted by a pancreatic neuroendocrine tumor, and that
was Steve Jobs. He was one of the big reasons why I took
on that project as well, trying to figure out not only what
these tumorigenic cells were and how they behaved,
but also how we could target them and potentially find
additional therapeutic avenues for this type of tumor.
That was one of my main objectives during my
PhD and it all tied into this molecule that Irv Weisman
discovered to be a “don’t-eat-me” signal. His lab identified
CD47 as a cell surface molecule that was initially looked
at as a cancer stem cell marker. What he quickly found
was that it was expressed not just in cancers with a stem
cell component but also in all the other cancer cells that
we tested. CD47 acts as the “don’t-eat-me” signal, so
it interacts with SIRP receptors on macrophages and
basically inactivates macrophages from performing
phagocytosis. This is one of the ways cancer cells are
able to evade immune surveillance, and by blocking
CD47 signaling, we were able to essentially re-awaken
the immune system, uncloak the cancers, and allow for
immune destruction of cancer cells. We demonstrated
this in vitro and in vivo with animal models and across
many different cancer types. This combined work by many
talented people in Dr. Weisman’s lab demonstrated the
preclinical evidence for the efficacy of CD47 therapies,
which lead to the creation of Irv’s company Forty Seven,
Inc. [The company] is now carrying out the clinical trials
that will hopefully be bringing this to market soon, and
the early results are very promising.
Can you talk about your decision to pursue academic
medicine and what brought you to Jefferson?
I’m really excited about being here at Jefferson for a lot
of reasons. My passion is in trying to bridge science and
surgery, so [after residency] I wanted to continue my
surgical training, and I did a fellowship at MD Anderson
in complex general surgical oncology, which was a
tremendous experience as well. I was able to connect
with James Allison, Padmanee Sharma, and Anirban
Maitra about what it takes to do high end science, and
they provided some real insight into taking the next steps
toward that goal. I became even more convinced that I
wanted to do both [surgery and research]. I came out of
MD Anderson with great training in surgical oncology and
a specific interest and focus in hepatopancreaticobiliary
surgery, but also wanting to do cutting edge research.
When I was coming out of fellowship, I was looking for
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a job that would provide both of those and [Jefferson]
did just that. It’s a tremendous institution that has a
commitment and real expertise in both the surgical
aspect and scientific and research aspects of pancreas
cancer. Being able to operate with Dr. Charles Yeo and
Dr. Harish Lavu and learn from them on the operative
side and then also do high-end research with Dr. Scott
Waldman and Dr. Jonathan Brody and the rest of the
scientific community here [made it] a no-brainer to come
here. I felt like this was a tremendous opportunity for me
to operate at a very high end on both of those aspects.
I think equally exciting to me is the opportunity to reengage with medical students and residents. Perhaps
the only disadvantage of training at MD Anderson was
the paucity of interactions with residents and medical
students. I really missed the teaching and team dynamic
from my previous experiences at Stanford. I’m looking
forward to re-engaging with the medical student and
resident community. I think trainees provide a boundless
source of energy and enthusiasm and ideas. You are
really the engine for academic medicine and discovery.
So, I’m really excited to be at a place that has such strong
medical student and resident communities.
How do you see cancer treatments and surgical
oncology changing in the coming decades?
I’ve always seen surgical intervention as being the
cornerstone for cancer treatment. I think there’s
always going to be a time where surgical intervention is
warranted. The indications may become more specific,
but I think taking out the primary tumor is always
going to be important. I think that a lot of targeted
therapies that are being discovered and, in particular,
the immunotherapies and checkpoint inhibitors, of
which CD47 is one, are going to play a larger and larger
role. Especially as we figure out how cancers protect
themselves from such powerful therapies, we’ll be
able to do combination therapies that really allow us to
push the envelope and - hopefully, at one point - make
each individual cancer a more manageable disease. My
focus is on pancreatic cancer, which is one of the most
challenging cancers. I’d like to be part of what I think is
going to be a real revolution in the next decade or two in
how we treat pancreas cancer.
What are some barriers that you see to people
accessing these advancements in cancer treatment?
What are your thoughts on how to help overcome these
barriers?
I think a lot of that really comes down to health policy. I
fully recognize that developing these drugs and making
these new discoveries - taking a discovery from inception

to putting it in the human - takes an enormous amount of
effort and an enormous investment. So, I fully understand
the more practical aspect of drug development and
discovery and the need for investment in research and
development. But then, you make a point about this
being accessible to people, which I think is multifaceted
and very complicated. Otherwise it would already be
solved.
I think it goes hand-in-hand with industry, which has
recognized that in a lot of ways. A lot of pharmaceutical
companies have outreach measures to make their drugs
more available to a broader portion of the population,
especially the uninsured or underinsured. There’s also
a policy component, whether we talk about how we
restructure our healthcare system or our insurance
system in such a way that more people have access
to coverage. So, I think it will require cooperation from
the pharmaceutical industry, the insurance industry,
healthcare providers, and government. There’s
the corporate level on the drug development and
pharmaceutical side, the insurance industry and making
sure that reforms are made there - [so] more people have
more access and better quality health insurance - and
then the governmental side, essentially facilitating. I
think the government works best as a facilitator of these
different processes.
Now that you’re a practicing surgeon and a researcher,
could you discuss work-life balance and how it’s
changed throughout your career? What advice do you
have for medical students interested in surgery?
Yeah! I think that’s an interesting topic. I kind of view it as
a triangle. You have your clinical aspects - taking care of
patients and operating - and that’s certainly paramount
because it’s how you affect your patients individually
and their families. You have this tremendous impact on
those people every day, and it’s extremely rewarding.
That’s one of the things that fuels surgeons: to be able
to make that difference for that particular person and
[give them] the chance to heal. Everything that we’ve all
essentially aspired to be as doctors - that’s what that
opportunity allows. Another apex of that triangle is the
research component, and that’s how we touch the lives
of the broader population. The discoveries you make in
that area are potentially the ones that are going to impact
the most people. So, that has obvious importance to it.
And the other side of that triangle is family. I think those
are the triumvirate of success or happiness, and I think
that you have to figure out a way to nurture all of those
areas, and it’s not easy. At times, one will suffer at the
expense of the others, but you have to figure out a way to
make that one area not be neglected for too long. That is

where the balance comes in.
I’m not really sure “work-life balance” is the right term.
I think you’re always in a state of imbalance, and you just
have to find a way where that imbalance is somewhat
shared. I think at times family life is going to suffer a
little bit, but you have to figure out a way to recharge
those batteries, to replenish that, and to re-water that
tree. And, similarly, I think there will be times where you’ll
cut back on some of the patient work that you’ll do - or,
sometimes, the research aspects - to make room for
the other of the three pieces. I think the idea that you
can have all things at all times is probably a disservice
to people that are hearing that advice and going into
medical school thinking that’s possible.
I don’t mean to suggest that it’s not a worthwhile
endeavor. I think that it’s one that you have to go into with
eyes wide open. It all becomes about time management.
I think the more that you do, the more focused you
become on the things that you want to focus on, and the
things that you previously engaged in but weren’t really
at the core of who you are or what you really enjoy go
by the wayside. And I think that’s good in a lot of ways,
because it really allows you to focus on the things that
are important to you.
What do you like to do outside of work?
I used to be a competitive weight-lifter, and I even won a
national championship in powerlifting. I still enjoy lifting
from time to time, but I no longer compete. Now the bulk
of my time is spent with patients, in the lab, or with my
family. I have a daughter and a baby boy, and they keep
me and my wife pretty busy at home.
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